ADPT Adaptive Biotechnologies Corp

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development and commercialization of immune medicine products using proprietary sequencing to decode adaptive immune system for diagnostics and therapeutics
• • New focus in 2024: Reorganization into MRD business specializing in clonoSEQ testing and Immune Medicine (IM) business emphasizing immune receptor sequencing and TCR-antigen mapping
• • Strategic shift: Expanded commercial promotion of blood-based clonoSEQ MRD tests in NHL subtypes (DLBCL, MCL) with increased payor coverage, including Medicare for MCL recurrence monitoring
• • Quantitative highlight: Revenue $277M in 2025, up 55% YoY; clonoSEQ test volume 105,587, up 39% YoY; paired TCR-antigen mappings increased from 2M to over 5M
• • Noteworthy fact: Entered two 2025 non-exclusive collaborations with Pfizer to apply TCR discovery and immune receptor-antigen mapping to rheumatoid arthritis and broader immunology

Risk Factors

• • Regulatory risk: Potential non-coverage or inadequate reimbursement for clonoSEQ diagnostic tests by private and government payors affecting revenue
• • Geopolitical/macroeconomic risk: Dependence on Illumina as sole supplier for sequencers and reagents, risking operational disruption if supply is interrupted
• • Operational risk: Reliance on single-source suppliers (Illumina NextSeq and NovaSeq X Plus Systems) for lab equipment and reagents requiring costly and time-consuming revalidation if changed
• • Competitive risk: Pressure from competitors may reduce coverage and reimbursement rates for clonoSEQ and other diagnostic products
• • Financial risk: Significant net losses with $59.5M loss in 2025, $1.4B accumulated deficit, requiring substantial investment to reach profitability

Management Discussion & Analysis

• • Revenue $277.0M in 2025, up 55% YoY from $179.0M in 2024; MRD revenue $212.3M (+46%) and Immune Medicine $64.6M (+93%)
• • Operating margin negative: loss from operations $(57.1)M in 2025 vs $(162.5)M in 2024; Adjusted EBITDA positive $12.2M in 2025 vs loss $(80.4)M prior
• • Best segment MRD: Adjusted EBITDA $15.2M vs $(41.2)M; worst segment Immune Medicine Adjusted EBITDA $10.3M vs $(24.4)M, driven by Genentech Agreement termination
• • Cash $240.2M as of Dec 31, 2025, down from $256.0M in 2024; no mention of buybacks or dividends; capex embedded in R&D and cost of revenue (no explicit capex figure)
• • Management expects MRD revenue growth short/long term; Immune Medicine revenue to decline short term due to Genentech termination; rising sales/marketing expenses in short term

What are the latest ADPT SEC filings in 2026?

Adaptive Biotechnologies Corp (ADPT) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on July 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ADPT file its most recent 10-K annual report?

Adaptive Biotechnologies Corp (ADPT) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ADPT 10-Q quarterly reports?

Adaptive Biotechnologies Corp (ADPT)'s most recent 10-Q quarterly report was filed on May 5, 2026. SignalX displays every ADPT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ADPT filed recently?

Adaptive Biotechnologies Corp (ADPT)'s most recent 8-K was filed on July 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ADPT insider trading activity (Form 4)?

SignalX aggregates every ADPT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ADPT file with the SEC?

Adaptive Biotechnologies Corp (ADPT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ADPT filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Adaptive Biotechnologies Corp (ADPT).

What is ADPT's SEC CIK number?

Adaptive Biotechnologies Corp (ADPT)'s SEC CIK (Central Index Key) number is 1478320. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1478320 to look up all ADPT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ADPT return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Adaptive Biotechnologies Corp (ADPT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.